

# Wei Zheng

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8316373/publications.pdf>

Version: 2024-02-01

38  
papers

882  
citations

516710

16  
h-index

477307

29  
g-index

38  
all docs

38  
docs citations

38  
times ranked

936  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression. <i>Journal of Affective Disorders</i> , 2022, 300, 109-113.	4.1	15
2	The effectiveness of repeated intravenous ketamine on subjective and objective psychosocial function in patients with treatment-resistant depression and suicidal ideation. <i>Journal of Affective Disorders</i> , 2022, 304, 78-84.	4.1	6
3	Functional connectivity between the habenula and default mode network and its association with the antidepressant effect of ketamine. <i>Depression and Anxiety</i> , 2022, 39, 352-362.	4.1	9
4	Plasma VEGF Concentrations and Ketamine's Effects on Suicidal Ideation in Depression With Suicidal Ideation. <i>Frontiers in Psychiatry</i> , 2022, 13, 855995.	2.6	4
5	Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression. <i>Journal of Psychopharmacology</i> , 2021, 35, 159-167.	4.0	9
6	A Preliminary Study of Adjunctive Nonconvulsive Electrotherapy for Treatment-Refractory Depression. <i>Psychiatric Quarterly</i> , 2021, 92, 311-320.	2.1	5
7	Association of plasma VEGF levels and the antidepressant effects of ketamine in patients with depression. <i>Therapeutic Advances in Psychopharmacology</i> , 2021, 11, 204512532110143.	2.7	5
8	Serum BDNF levels and the antidepressant effects of electroconvulsive therapy with ketamine anaesthesia: a preliminary study. <i>PeerJ</i> , 2021, 9, e10699.	2.0	6
9	Working memory associated with anti-suicidal ideation effect of repeated-dose intravenous ketamine in depressed patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 431-438.	3.2	17
10	Sleep improvement is associated with the antidepressant efficacy of repeated-dose ketamine and serum BDNF levels: a post-hoc analysis. <i>Pharmacological Reports</i> , 2021, 73, 594-603.	3.3	15
11	The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality. <i>Journal of Psychiatric Research</i> , 2021, 144, 312-319.	3.1	9
12	Association of VEGF With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression. <i>Frontiers in Psychiatry</i> , 2021, 12, 780975.	2.6	6
13	Association between plasma levels of BDNF and the antisuicidal effects of repeated ketamine infusions in depression with suicidal ideation. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532097379.	2.7	7
14	Alterations of multiple peripheral inflammatory cytokine levels after repeated ketamine infusions in major depressive disorder. <i>Translational Psychiatry</i> , 2020, 10, 246.	4.8	42
15	Volumetric changes in subcortical structures following repeated ketamine treatment in patients with major depressive disorder: a longitudinal analysis. <i>Translational Psychiatry</i> , 2020, 10, 264.	4.8	28
16	&lt;p&gt;Serum BDNF Levels are Not Associated with the Antidepressant Effects of Nonconvulsive Electrotherapy&lt;/p&gt;. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 1555-1560.	2.2	4
17	Predictors of response to repeated ketamine infusions in depression with suicidal ideation: An ROC curve analysis. <i>Journal of Affective Disorders</i> , 2020, 264, 263-271.	4.1	15
18	&lt;p&gt;BDNF and the Antidepressant Effects of Ketamine and Propofol in Electroconvulsive Therapy: A Preliminary Study&lt;/p&gt;. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 901-908.	2.2	9

#	ARTICLE	IF	CITATIONS
19	Neurocognitive effects of six ketamine infusions and the association with antidepressant effects in treatment-resistant bipolar depression: a preliminary study. <i>PeerJ</i> , 2020, 8, e10208.	2.0	5
20	Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2019, 259, 1-6.	4.1	27
21	Adjunctive minocycline for major mental disorders: A systematic review. <i>Journal of Psychopharmacology</i> , 2019, 33, 1215-1226.	4.0	27
22	Association between depression subtypes and response to repeated-dose intravenous ketamine. <i>Acta Psychiatrica Scandinavica</i> , 2019, 140, 446-457.	4.5	16
23	A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation. <i>Journal of Affective Disorders</i> , 2019, 251, 205-212.	4.1	46
24	Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder. <i>Journal of Psychopharmacology</i> , 2019, 33, 494-501.	4.0	35
25	Neurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder. <i>Journal of Affective Disorders</i> , 2019, 246, 241-247.	4.1	50
26	Adjunctive raloxifene for postmenopausal women with schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. <i>Schizophrenia Research</i> , 2018, 197, 288-293.	2.0	25
27	Comparison of comorbid depression between irritable bowel syndrome and inflammatory bowel disease: A meta-analysis of comparative studies. <i>Journal of Affective Disorders</i> , 2018, 237, 37-46.	4.1	22
28	Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. <i>Psychological Medicine</i> , 2018, 48, 72-81.	4.5	29
29	Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression. <i>Journal of Psychopharmacology</i> , 2018, 32, 1118-1126.	4.0	53
30	Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. <i>Journal of Psychiatric Research</i> , 2018, 106, 61-68.	3.1	119
31	Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression. <i>Brain, Behavior, and Immunity</i> , 2018, 74, 205-212.	4.1	63
32	Association of sleep duration with sleep disturbances, quality of life, and sociodemographic factors in general hospital outpatients. <i>Perspectives in Psychiatric Care</i> , 2018, 54, 422-427.	1.9	5
33	Amantadine for Antipsychotic-Related Weight Gain. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 341-346.	1.4	16
34	Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials. <i>European Neuropsychopharmacology</i> , 2017, 27, 8-18.	0.7	69
35	Integrating the GPCR transactivation-dependent and biased signalling paradigms in the context of PAR1 signalling. <i>British Journal of Pharmacology</i> , 2016, 173, 2992-3000.	5.4	12
36	Adjunctive Electroconvulsive Therapy for Schizophrenia. <i>Journal of ECT</i> , 2016, Publish Ahead of Print, .	0.6	1

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 385-398.	4.5	51
38	Electroconvulsive Therapy Alone for Schizophrenia. <i>Journal of ECT</i> , 2016, Publish Ahead of Print, .	0.6	0